RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 137 filers reported holding RIGEL PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 3.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $246,874 | -16.0% | 228,595 | +0.3% | 0.00% | – |
| Q2 2023 | $293,965 | +99212.5% | 227,880 | +1.8% | 0.00% | – |
| Q1 2023 | $296 | -9.5% | 223,880 | +2.6% | 0.00% | – |
| Q4 2022 | $327 | -99.9% | 218,270 | +2.5% | 0.00% | – |
| Q3 2022 | $251,000 | +16.7% | 213,000 | +12.0% | 0.00% | – |
| Q2 2022 | $215,000 | -60.8% | 190,166 | +3.7% | 0.00% | -100.0% |
| Q1 2022 | $548,000 | +13.5% | 183,347 | +0.6% | 0.00% | 0.0% |
| Q4 2021 | $483,000 | -28.3% | 182,238 | -1.9% | 0.00% | 0.0% |
| Q3 2021 | $674,000 | -14.5% | 185,763 | +2.3% | 0.00% | 0.0% |
| Q2 2021 | $788,000 | +16.7% | 181,541 | -8.0% | 0.00% | 0.0% |
| Q1 2021 | $675,000 | -8.4% | 197,430 | -6.2% | 0.00% | 0.0% |
| Q4 2020 | $737,000 | +54.8% | 210,470 | +6.1% | 0.00% | 0.0% |
| Q3 2020 | $476,000 | +15.0% | 198,330 | -12.2% | 0.00% | 0.0% |
| Q2 2020 | $414,000 | +15.0% | 226,015 | -2.1% | 0.00% | 0.0% |
| Q1 2020 | $360,000 | -27.9% | 230,946 | -0.9% | 0.00% | 0.0% |
| Q4 2019 | $499,000 | +16.6% | 232,946 | +1.7% | 0.00% | 0.0% |
| Q3 2019 | $428,000 | -28.2% | 229,049 | +0.3% | 0.00% | 0.0% |
| Q2 2019 | $596,000 | +8.8% | 228,457 | +7.1% | 0.00% | 0.0% |
| Q1 2019 | $548,000 | +9.2% | 213,298 | -2.2% | 0.00% | 0.0% |
| Q4 2018 | $502,000 | +6.6% | 218,130 | +48.8% | 0.00% | 0.0% |
| Q3 2018 | $471,000 | +7.0% | 146,640 | -5.7% | 0.00% | 0.0% |
| Q2 2018 | $440,000 | -7.2% | 155,515 | +16.3% | 0.00% | 0.0% |
| Q1 2018 | $474,000 | +3.3% | 133,770 | +13.1% | 0.00% | 0.0% |
| Q4 2017 | $459,000 | +27.5% | 118,290 | -16.6% | 0.00% | 0.0% |
| Q3 2017 | $360,000 | -5.8% | 141,884 | +1.5% | 0.00% | 0.0% |
| Q2 2017 | $382,000 | -12.6% | 139,814 | +6.0% | 0.00% | 0.0% |
| Q1 2017 | $437,000 | +68.1% | 131,904 | +20.6% | 0.00% | 0.0% |
| Q4 2016 | $260,000 | -42.4% | 109,379 | -11.0% | 0.00% | 0.0% |
| Q3 2016 | $451,000 | +63.4% | 122,913 | -0.8% | 0.00% | 0.0% |
| Q2 2016 | $276,000 | +24.9% | 123,963 | +16.6% | 0.00% | 0.0% |
| Q1 2016 | $221,000 | -28.7% | 106,334 | +4.0% | 0.00% | 0.0% |
| Q4 2015 | $310,000 | +31.9% | 102,229 | +7.4% | 0.00% | 0.0% |
| Q3 2015 | $235,000 | -20.1% | 95,154 | +4.0% | 0.00% | 0.0% |
| Q2 2015 | $294,000 | -37.6% | 91,455 | -30.6% | 0.00% | 0.0% |
| Q1 2015 | $471,000 | +65.8% | 131,845 | +5.4% | 0.00% | 0.0% |
| Q4 2014 | $284,000 | +27.4% | 125,145 | +9.0% | 0.00% | 0.0% |
| Q3 2014 | $223,000 | -46.5% | 114,770 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $417,000 | -7.7% | 114,770 | -1.4% | 0.00% | 0.0% |
| Q1 2014 | $452,000 | +31.8% | 116,400 | -3.2% | 0.00% | 0.0% |
| Q4 2013 | $343,000 | -25.1% | 120,240 | -6.0% | 0.00% | 0.0% |
| Q3 2013 | $458,000 | +6.5% | 127,940 | -0.6% | 0.00% | 0.0% |
| Q2 2013 | $430,000 | – | 128,718 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
| Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
| ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
| GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
| NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
| Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.03% |
| XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |